Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (4988)	8/2/2000 2:48:29 PM
From: Montana Wildhack	Read Replies (1) \| Respond to of 14101

CG, "Wolf, the pharmacy (or rather should I say the pharmacist) is NOT the primary driver for prescription sales. This belongs to the physician. That's why almost all marketing efforts go towards trying to persuade the physician to use the product." I agree. The comment about $45 to the pharmacies is to quantify revenue potential. As I've posted weeks back, the doctors will go to Pennsaid as the first alternative because it is proven safe and effective. I've also posted that Dimethaid is making 15ml and 60ml size Pennsaid. The 15ml is for samples for use just as you say. Wolf

To: Cal Gary who wrote (4988)	8/10/2000 2:54:48 PM
From: Jeff Chan	Respond to of 14101

Hi Cal, Sorry it's taken me this long to respond...I don't really monitor the thread too much these days...a little PO'd at how long this business is taking and seeing DMX drift lower and lower. Anyhow, to answer your question, let me say that I've never been to one of these institutional roadshows. However, because: a) the drug is not approved for distribution b) it is (or will be) a prescription drug it's highly unlikely that even samples would be distributed. Generally, when I go to Pharmacy conferences, I see a sample of the container only. ...hope this helps Jeff C